GURUFOCUS.COM » STOCK LIST » Industrials » Business Services » Proto Script Pharmaceutical Corp (OTCPK:PSCR) » Definitions » Intrinsic Value: Projected FCF

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Intrinsic Value: Projected FCF : $0.00 (As of May. 24, 2024)


View and export this data going back to 2011. Start your Free Trial

What is Proto Script Pharmaceutical Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2024-05-24), Proto Script Pharmaceutical's Intrinsic Value: Projected FCF is $0.00. The stock price of Proto Script Pharmaceutical is $0.0002. Therefore, Proto Script Pharmaceutical's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Proto Script Pharmaceutical's Intrinsic Value: Projected FCF or its related term are showing as below:

PSCR's Price-to-Projected-FCF is not ranked *
in the Business Services industry.
Industry Median: 0.96
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Proto Script Pharmaceutical Intrinsic Value: Projected FCF Historical Data

The historical data trend for Proto Script Pharmaceutical's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Proto Script Pharmaceutical Intrinsic Value: Projected FCF Chart

Proto Script Pharmaceutical Annual Data
Trend May12 May13 May14 May15 May16
Intrinsic Value: Projected FCF
- - - - -

Proto Script Pharmaceutical Quarterly Data
Nov12 Feb13 May13 Aug13 Nov13 Feb14 May14 Aug14 Nov14 Feb15 May15 Aug15 Nov15 Feb16 May16 Sep16 Dec16 Mar17 Jun17 Sep17
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - -0.01 -0.04 -0.05

Competitive Comparison of Proto Script Pharmaceutical's Intrinsic Value: Projected FCF

For the Specialty Business Services subindustry, Proto Script Pharmaceutical's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Proto Script Pharmaceutical's Price-to-Projected-FCF Distribution in the Business Services Industry

For the Business Services industry and Industrials sector, Proto Script Pharmaceutical's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Proto Script Pharmaceutical's Price-to-Projected-FCF falls into.



Proto Script Pharmaceutical Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)



Proto Script Pharmaceutical  (OTCPK:PSCR) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Proto Script Pharmaceutical's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=0.0002/
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Proto Script Pharmaceutical Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Proto Script Pharmaceutical's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Proto Script Pharmaceutical (Proto Script Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
9830 6th Street, Suite 103, Rancho Cucamonga, CA, USA, 91730
Proto Script Pharmaceutical Corp is primarily in the business of repair power wheelchairs and scooters, which are classified as durable medical equipment (DME) products and reimbursable by healthcare insurance providers. It has various contracts with state and governmental insurance providers, among others. These contracts provide the company with the right to sell and repair DME and its health care insurance contracts allow it the ability to service patients nationally. The group currently has its presence of repair facilities in Las Vegas, Nevada, Rancho-Cucamonga, and Anaheim, California.

Proto Script Pharmaceutical (Proto Script Pharmaceutical) Headlines

No Headlines